Trial Profile

Prospective Non-Interventional Observational Study of Use of Triumeq and Corresponding Monitoring Measures in Clinical Practice in Germany

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abacavir/dolutegravir/lamivudine (Primary)
Indications HIV infections
Focus Adverse reactions
Acronyms TRIUMPH
Sponsors ViiV Healthcare

Most Recent Events

07 Feb 2019 Status changed from active, no longer recruiting to completed.
31 Oct 2018 Results of the second interim analysis (Data cut off: 31 Dec 2017) presented at the 14th International Congress on Drug Therapy and HIV Infection
27 Oct 2017 First interim results (n=392; data cut off: 31 Dec 2016) presented at the 16th European AIDS Conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com